Literatur: Tirofiban

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Tirofiban

  • 1. “A Comparison of Aspirin Plus Tirofiban With Aspirin Plus Heparin for Unstable Angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators,” N Engl J Med, 1998, 338(21):1498-505. [PubMed 9599104]
  • 2. Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(18):e426-579. [PubMed 21444888]
  • 3. Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation, 2004, 110(5):588-636. [PubMed 15289388]
  • 4. Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” Circulation, 1999, 99(21):2720-32. [PubMed 10351964]
  • 5. Boztosun B, Olcay A, Avci A, et al, "Treatment of Acute Myocardial Infarction in Pregnancy With Coronary Artery Balloon Angioplasty and Stenting: Use of Tirofiban and Clopidogrel," Int J Cardiol, 2008, 127(3):413-6. [PubMed 17655948]
  • 6. Brener SJ, Barr LA, Burchenal JE, et al, “Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,” ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, Circulation, 1998, 98(8):734-41. [PubMed 9727542]
  • 7. Braunwald E, Antman EM, Beasley JW, et al, “ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),” J Am Coll Cardiol, 2002, 40(7):1366-74. [PubMed 12383588]
  • 8. Cannon CP, Weintraub WS, Demopoulos LA, et al, “Comparison of Early Invasive and Conservative Strategies in Patients With Unstable Coronary Syndromes Treated With the Glycoprotein IIb/IIIa Inhibitor Tirofiban,” N Engl J Med, 2001, 344(25):1879-87. [PubMed 11419424]
  • 9. Demirkan B, Guray Y, Guray U, et al, “Differential Diagnosis and Management of Acute Profound Thrombocytopenia by Tirofiban: A Case Report,” J Thromb Thrombolysis, 2006, 22(1):77-8. [PubMed 16786237]
  • 10. “Effects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis,” Circulation, 1997, 96(5):1445-53. [PubMed 9315530]
  • 11. Giugliano RP, White JA, Bode C, et al, “Early Versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes,” N Engl J Med, 2009, 360(21):2176-90. [PubMed 19332455]
  • 12. Hamm CW, Heeschen C, Goldmann B, et al, “Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,” N Engl J Med, 1999, 340(21):1623-9. [PubMed 10341274]
  • 13. Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42. [PubMed 22064600]
  • 14. Huxtable LM, Tafreshi MJ, and Rakkar AN, “Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,” Am J Cardiol, 2006, 97(3):426-9. [PubMed 16442410]
  • 15. “Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor With Tirofiban in Unstable Angina and Non-Q-Wave Myocardial Infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators,” N Engl J Med, 1998, 338(21):1488-97. [PubMed 9599103]
  • 16. “Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,” N Engl J Med, 1998, 339(7):436-43. [PubMed 9705684]
  • 17. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 18. Lincoff AM, Califf RM, Anderson KM, et al, “Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,” J Am Coll Cardiol, 1997, 30(1):149-56. [PubMed 9207636]
  • 19. Lincoff AM, Califf RM, Moliterno DJ, et al, “Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,” N Engl J Med, 1999, 341(5):319-27. [PubMed 10423466]
  • 20. Lincoff AM, Tcheng JE, Califf RM, et al, “Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,” Circulation, 1999, 99(15):1951-8. [PubMed 10208997]
  • 21. Llevadot J, Coulter SA, and Giugliano RP, “A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,” J Thromb Thrombolysis, 2000, 9(2):175-80. [PubMed 10613999]
  • 22. Topol EJ, Ferguson JJ, Weisman HF, et al, “Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta3 Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,” JAMA, 1997, 278(6):479-84. [PubMed 9256222]
  • 23. Topol EJ, Moliterno DJ, Herrmann HC, et al, “Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,” N Engl J Med, 2001, 344(25):1888-94. [PubMed 11419425]
  • 24. van den Merkhof LF, Zijlstra F, Olsson H, et al, “Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,” J Am Coll Cardiol, 1999, 33(6):1528-32. [PubMed 10334418]
  • 25. Valgimigli M, Campo G, Percoco G, et al, “Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-eluting or Uncoated Stents for Acute Myocardial Infarction: the MULTISTRATEGY Randomized Trial,” JAMA, 2008, 299(15):1788-99. [PubMed 18375998]
  • 26. Valgimigli M, Percoco G, Malagutti P, et al, “Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction: A Randomized Trial,” JAMA, 2005, 293(17):2109-17. [PubMed 15870414]
  • 27. Van’t Hof AW, ten Berg J, Heestermans T, et al, “Prehospital Initiation of Tirofiban in Patients with ST-elevation Myocardial Infarction Undergoing Primary Angioplasty (On-TIME 2): A Multicenter, Double-Blind, Randomized Controlled Trial,” Lancet, 2008, 372(9638):537-46. [PubMed 18707985]
  • 28. Wright RS, Anderson JL, Adams CD, et al, "2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons," J Am Coll Cardiol, 2011, 57(19):1920-59. [PubMed 21450428]

 

  top |

 

 

 
© 2022 Prof. Dr. J. Braun